As with all hormonal therapies, degarelix is commonly associated with hormonal side effects such as [[hot flashes]] and [[weight gain]].<ref name="Klotz"/><ref>Gittelman M, Pommerville PJ, Persson BE, et al (November 2008). A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J. Urol. '''180''': 1986-92.</ref><ref>Van Poppel H, Tombal B, de la Rosette JJ, et al (October 2008). Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur. Urol. '''54''': 805-13.</ref>  Due to its mode of administration ([[subcutaneous injection]]), degarelix is also associated with injection-site reactions such as injection-site pain, [[erythema]] or swelling.  Injection-site reactions are usually mild or moderate in intensity and occur predominantly after the first dose, decreasing in frequency thereafter.<ref name="Klotz"/>

 

